Industry News
Related Searches:
Filter by:
1291 - 1305 of 2385 results
August 24, 2009
UCB and Novartis entered into a license agreement for cardiovascular and diabetes products in Germany.
Read More »
August 21, 2009
Takeda Canada, Inc. has reacquired Canadian commercial rights to Actos, an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda licensed the drug to Lilly in 1999 as part of a worldwide agreement.
Read More »
August 21, 2009
XSpray Microparticles AB has launched its new GMP production facility in Malmo, Sweden.
Read More »
August 21, 2009
NextPharma has engaged the services of Ron Collins to represent its business development affairs in the eastern part of the U.S. and Canada in order to meet increased demand for its contract outsourcing services.
Read More »
August 21, 2009
Lonza has submitted a bid of approximately $460 million to acquire Patheon
Read More »
August 20, 2009
Catalent Pharma Solutions has launched its Development and Clinical Services unit
Read More »
August 19, 2009
Catalent's softgel facility in Buenos Aires successfully completed its first FDA cGMP audit and PAI
Read More »
August 19, 2009
CSL Biotherapies, a subsidiary of CSL Limited, received licensure from the FDA for its newest vaccine filling and packaging facility in Kankakee, IL.
Read More »
August 19, 2009
Covance has closed its transaction with Merck to provide genomics analysis services under a five-year contract valued at $145 million.
Read More »
August 18, 2009
Wyeth has recognized six suppliers for its Global Recognition for Outstanding Wyeth Suppliers (GROWS) awards program.
Read More »
August 18, 2009
Xceleron has signed a second Master Service Agreement with GlaxoSmithKline, under which Xceleron will provide analytical support to GSK and its affiliated research organizations.
Read More »
August 18, 2009
Amcor has offered to acquire parts of Alcan Packaging for $2.0 billion from Rio Tinto.
Read More »
August 17, 2009
SynCo Bio Partners entered a strategic partnership with Versartis, Inc. to produce Versartis’ lead drug candidate VRS-859, a GLP-1 analog for monthly dosing to treat type 2 diabetes.
Read More »
August 13, 2009
Catalent Pharma Solutions’ softgel manufacturing site in St. Petersburg, FL recently received a “Preferred Partner Award in Technology” from Wyeth Consumer Healthcare.The award, which recognizes Catalent’s support in 2008 for…
Read More »
August 11, 2009
FDA recommended approval to CDER for UPM to manufacture a low-dose tablet product
Read More »
1291 - 1305 of 2385 results
